Ultrasound Guided Femoral Nerve Block Versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate for Post-Operative Analgesia

NCT07838480 | Completed

• 1 other identifier: 36265MS728/11/24
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

Ultrasound Guided Femoral Nerve Block versus Adductor Canal Block by Using Bupivacaine and Magnesium Sulphate

Conditions

Knee Arthroscopic Surgery; Analgesia; Femoral Nerve Block (FNB)

Keywords

Femoral Nerve Block; Adductor Canal Block; Post-Operative Analgesia; knee Arthroscopic Surgeries

Outcome Measures

Primary Outcomes (1)

• The total post-operative morphine consumption

  24 hours postoperatively

Secondary Outcomes (1)

• Assessment of pain by Numeric Rating Scale

  Immediately after discharge to the PACU and ward at 1hour, 3hour, 6hour, 12hour, 24 hours.

Study Arms (3)

Group I: control group

PLACEBO COMPARATOR

Group I: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), with no intervention as a control group.

Procedure: Group I: control group

Group II: Ultrasound Guided Femoral Nerve Block

EXPERIMENTAL

Group II: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided FNB will be performed at the end of surgery, with 20 ml of 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml.

Procedure: Group II: Ultrasound Guided Femoral Nerve Block

Group III : Adductor Canal Block group

EXPERIMENTAL

Group III: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided ACB will be performed at the end of surgery, with 20 ml 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml.

Procedure: group III : Adductor Canal Block group

Interventions

Group I: control group PROCEDURE

Group I: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), with no intervention as a control group.

Group I: control group

Group II: Ultrasound Guided Femoral Nerve Block PROCEDURE

Group II: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided FNB will be performed at the end of surgery, with 20 ml of 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml.

Group II: Ultrasound Guided Femoral Nerve Block

group III : Adductor Canal Block group PROCEDURE

Group III: 30 Patients will receive the standard spinal anesthesia 12.5 mg (2.5 ml) of 0.5% hyperbaric bupivacaine with 25 µg of fentanyl (0.5 ml), then US guided ACB will be performed at the end of surgery, with 20 ml 0.25% bupivacaine with 5 ml of magnesium sulfate 10% solution (500 mg) with total volume of 25 ml.

Group III : Adductor Canal Block group

Eligibility Criteria

• Age: 21 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Age 21-60 years,
• both sexes, American Society of Anesthesiologists classification I-II and - -patients scheduled for elective Knee arthroscopic surgeries under spinal anesthesia.

You may not qualify if:

• Patient refusal.
• Patients on chronic pain medications or have a history of substance abuse.
• Patients who are unable to describe their postoperative pain (neuropsychiatric disorder).
• Patients with a history of coagulopathy.
• Patient with morbid obesity (body mass index ≥40 kg/m2).
• Patients with known local anesthetics and opioid allergy.
• Patients with infection at the site of the needle puncture.
• Patients with major respiratory, cardiac, renal or hepatic disorders.
• Patients on calcium channel blockers.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, Egypt

Location

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Anesthesia, Surgical Intensive Care and Pain Management

Study Record Dates

• First Submitted: September 10, 2026
• First Posted: September 24, 2026
• Study Start: November 30, 2024
• Primary Completion: November 30, 2025
• Study Completion: November 30, 2025
• Last Updated: September 24, 2026

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF

Locations

EG (1)